---
document_datetime: 2025-12-02 05:11:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ilumetri.html
document_name: ilumetri.html
version: success
processing_time: 0.1165897
conversion_datetime: 2025-12-24 05:44:22.175548
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ilumetri

[RSS](/en/individual-human-medicine.xml/65598)

##### Authorised

This medicine is authorised for use in the European Union

tildrakizumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ilumetri](#news-on)
- [More information on Ilumetri](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ilumetri is a medicine that acts on the immune system and is used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease for whom treatments applied to the skin are not suitable.

Ilumetri contains the active substance tildrakizumab.

Expand section

Collapse section

## How is Ilumetri used?

Ilumetri can only be obtained with a prescription and should be used under the supervision of a doctor experienced in diagnosing and treating plaque psoriasis.

Ilumetri is available as a solution in pre-filled syringes for injection under the skin. The recommended dose is one 100 mg injection, followed by a further dose after 4 weeks and then an injection every 12 weeks. The dose may be increased to 200 mg in certain patients, for example patients badly affected by the disease or with bodyweight over 90 kg. The doctor may decide to stop treatment if the condition does not improve after 28 weeks.

After training, patients may inject Ilumetri themselves if the doctor considers it appropriate.

For more information about using Ilumetri, see the package leaflet or contact your doctor or pharmacist.

## How does Ilumetri work?

The active substance in Ilumetri, tildrakizumab, is a monoclonal antibody (a type of protein) which is designed to attach to interleukin 23 and block its activity. Interleukin 23 is a substance that controls the growth and maturation of some types of T cells. These T cells, which are part of the immune system (the body's natural defences), are involved in causing inflammation that is linked to the development of plaque psoriasis. By blocking the action of interleukin 23, Ilumetri reduces inflammation and symptoms associated with the disease.

## What benefits of Ilumetri have been shown in studies?

Two main studies involving adults found Ilumetri effective for treating moderate to severe plaque psoriasis in patients for whom treatments applied to the skin did not work well enough.

The first study involving 771 patients compared Ilumetri with placebo (a dummy treatment). After 12 weeks, 64% and 62% of patients given 100 mg and 200 mg Ilumetri respectively had at least a 75% improvement in disease severity compared with 6% of those given placebo. Additionally, 58% of those given 100 mg and 59% of those given 200 mg had almost complete skin clearance compared with 7% given placebo.

The second study involving 1,090 patients compared Ilumetri with placebo and with etanercept (another psoriasis medicine). After 12 weeks, 61% and 66% of patients given 100 mg and 200 mg Ilumetri respectively had at least 75% improvement in severity compared with 48% of those given etanercept and 6% given placebo. Of those given Ilumetri, 55% (for 100 mg) and 59% (for 200 mg) had almost complete skin clearance compared with 48% given etanercept and 5% given placebo.

## What are the risks associated with Ilumetri?

The most common side effects with Ilumetri are upper respiratory tract (nose and throat) infections (which may affect more than 1 in 10 people). Headache, gastroenteritis (diarrhoea and vomiting), nausea (feeling sick), diarrhoea, pain at the site of the injection and back pain may affect up to 1 in 10 people.

Ilumetri must not be used in patients who have a serious ongoing infection such as tuberculosis. For the full list of side effects and restrictions with Ilumetri, see the package leaflet.

## Why is Ilumetri authorised in the EU?

Ilumetri is effective in treating psoriasis and some patients can experience total clearing of their psoriasis. Patients do not experience many side effects. Information on the use of Ilumetri in the long term is limited and studies are ongoing. The European Medicines Agency decided that Ilumetri's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ilumetri?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ilumetri have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ilumetri are continuously monitored. Side effects reported with Ilumetri are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ilumetri

Ilumetri received a marketing authorisation valid throughout the EU on 17 September 2018.

Ilumetri : EPAR - Medicine overview

Reference Number: EMA/621733/2018

English (EN) (74.73 KB - PDF)

**First published:** 09/10/2018

[View](/en/documents/overview/ilumetri-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-293)

български (BG) (102.83 KB - PDF)

**First published:**

09/10/2018

[View](/bg/documents/overview/ilumetri-epar-medicine-overview_bg.pdf)

español (ES) (75.13 KB - PDF)

**First published:**

09/10/2018

[View](/es/documents/overview/ilumetri-epar-medicine-overview_es.pdf)

čeština (CS) (100.2 KB - PDF)

**First published:**

09/10/2018

[View](/cs/documents/overview/ilumetri-epar-medicine-overview_cs.pdf)

dansk (DA) (73.2 KB - PDF)

**First published:**

09/10/2018

[View](/da/documents/overview/ilumetri-epar-medicine-overview_da.pdf)

Deutsch (DE) (76.1 KB - PDF)

**First published:**

09/10/2018

[View](/de/documents/overview/ilumetri-epar-medicine-overview_de.pdf)

eesti keel (ET) (73.24 KB - PDF)

**First published:**

09/10/2018

[View](/et/documents/overview/ilumetri-epar-medicine-overview_et.pdf)

ελληνικά (EL) (103.11 KB - PDF)

**First published:**

09/10/2018

[View](/el/documents/overview/ilumetri-epar-medicine-overview_el.pdf)

français (FR) (75.8 KB - PDF)

**First published:**

09/10/2018

[View](/fr/documents/overview/ilumetri-epar-medicine-overview_fr.pdf)

hrvatski (HR) (93.88 KB - PDF)

**First published:**

09/10/2018

[View](/hr/documents/overview/ilumetri-epar-medicine-overview_hr.pdf)

italiano (IT) (74.42 KB - PDF)

**First published:**

09/10/2018

[View](/it/documents/overview/ilumetri-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (97.17 KB - PDF)

**First published:**

09/10/2018

[View](/lv/documents/overview/ilumetri-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (96.94 KB - PDF)

**First published:**

09/10/2018

[View](/lt/documents/overview/ilumetri-epar-medicine-overview_lt.pdf)

magyar (HU) (93.17 KB - PDF)

**First published:**

09/10/2018

[View](/hu/documents/overview/ilumetri-epar-medicine-overview_hu.pdf)

Malti (MT) (98.77 KB - PDF)

**First published:**

09/10/2018

[View](/mt/documents/overview/ilumetri-epar-medicine-overview_mt.pdf)

Nederlands (NL) (74.18 KB - PDF)

**First published:**

09/10/2018

[View](/nl/documents/overview/ilumetri-epar-medicine-overview_nl.pdf)

polski (PL) (99.53 KB - PDF)

**First published:**

09/10/2018

[View](/pl/documents/overview/ilumetri-epar-medicine-overview_pl.pdf)

português (PT) (74.95 KB - PDF)

**First published:**

09/10/2018

[View](/pt/documents/overview/ilumetri-epar-medicine-overview_pt.pdf)

română (RO) (97.25 KB - PDF)

**First published:**

09/10/2018

[View](/ro/documents/overview/ilumetri-epar-medicine-overview_ro.pdf)

slovenčina (SK) (98.94 KB - PDF)

**First published:**

09/10/2018

[View](/sk/documents/overview/ilumetri-epar-medicine-overview_sk.pdf)

slovenščina (SL) (93.28 KB - PDF)

**First published:**

09/10/2018

[View](/sl/documents/overview/ilumetri-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.13 KB - PDF)

**First published:**

09/10/2018

[View](/fi/documents/overview/ilumetri-epar-medicine-overview_fi.pdf)

svenska (SV) (73.6 KB - PDF)

**First published:**

09/10/2018

[View](/sv/documents/overview/ilumetri-epar-medicine-overview_sv.pdf)

Ilumetri : EPAR - Risk management plan

English (EN) (2.27 MB - PDF)

**First published:** 09/10/2018

**Last updated:** 23/07/2024

[View](/en/documents/rmp-summary/ilumetri-epar-risk-management-plan_en.pdf)

## Product information

Ilumetri : EPAR - Product Information

English (EN) (1.91 MB - PDF)

**First published:** 09/10/2018

**Last updated:** 16/07/2025

[View](/en/documents/product-information/ilumetri-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-447)

български (BG) (2.02 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/bg/documents/product-information/ilumetri-epar-product-information_bg.pdf)

español (ES) (2.02 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/es/documents/product-information/ilumetri-epar-product-information_es.pdf)

čeština (CS) (2.27 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/cs/documents/product-information/ilumetri-epar-product-information_cs.pdf)

dansk (DA) (1.85 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/da/documents/product-information/ilumetri-epar-product-information_da.pdf)

Deutsch (DE) (2.18 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/de/documents/product-information/ilumetri-epar-product-information_de.pdf)

eesti keel (ET) (1.86 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/et/documents/product-information/ilumetri-epar-product-information_et.pdf)

ελληνικά (EL) (2.2 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/el/documents/product-information/ilumetri-epar-product-information_el.pdf)

français (FR) (1.97 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/fr/documents/product-information/ilumetri-epar-product-information_fr.pdf)

hrvatski (HR) (1.95 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/hr/documents/product-information/ilumetri-epar-product-information_hr.pdf)

íslenska (IS) (1.83 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/is/documents/product-information/ilumetri-epar-product-information_is.pdf)

italiano (IT) (2.23 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/it/documents/product-information/ilumetri-epar-product-information_it.pdf)

latviešu valoda (LV) (2.02 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/lv/documents/product-information/ilumetri-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.98 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/lt/documents/product-information/ilumetri-epar-product-information_lt.pdf)

magyar (HU) (1.9 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/hu/documents/product-information/ilumetri-epar-product-information_hu.pdf)

Malti (MT) (2.23 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/mt/documents/product-information/ilumetri-epar-product-information_mt.pdf)

Nederlands (NL) (2.03 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/nl/documents/product-information/ilumetri-epar-product-information_nl.pdf)

norsk (NO) (1.8 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/no/documents/product-information/ilumetri-epar-product-information_no.pdf)

polski (PL) (2.12 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/pl/documents/product-information/ilumetri-epar-product-information_pl.pdf)

português (PT) (1.93 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/pt/documents/product-information/ilumetri-epar-product-information_pt.pdf)

română (RO) (1.92 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/ro/documents/product-information/ilumetri-epar-product-information_ro.pdf)

slovenčina (SK) (1.96 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/sk/documents/product-information/ilumetri-epar-product-information_sk.pdf)

slovenščina (SL) (1.89 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/sl/documents/product-information/ilumetri-epar-product-information_sl.pdf)

Suomi (FI) (2.19 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/fi/documents/product-information/ilumetri-epar-product-information_fi.pdf)

svenska (SV) (1.9 MB - PDF)

**First published:**

09/10/2018

**Last updated:**

16/07/2025

[View](/sv/documents/product-information/ilumetri-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000261769 05/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ilumetri : EPAR - All Authorised presentations

English (EN) (97.36 KB - PDF)

**First published:** 09/10/2018

**Last updated:** 23/07/2024

[View](/en/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-297)

български (BG) (96.54 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/bg/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_bg.pdf)

español (ES) (80.86 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/es/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_es.pdf)

čeština (CS) (100.75 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/cs/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (83.46 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/da/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (81.62 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/de/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (85.07 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/et/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (93.03 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/el/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_el.pdf)

français (FR) (81.44 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/fr/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (98.19 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/hr/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (93.55 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/is/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_is.pdf)

italiano (IT) (89.41 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/it/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (90.51 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/lv/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (90.24 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/lt/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (103.29 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/hu/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (101.18 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/mt/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (85.37 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/nl/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (115.19 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/no/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_no.pdf)

polski (PL) (96.4 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/pl/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_pl.pdf)

português (PT) (90.09 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/pt/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_pt.pdf)

română (RO) (107.32 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/ro/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (93.64 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/sk/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (80.17 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/sl/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (79.21 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/fi/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (100.55 KB - PDF)

**First published:**

09/10/2018

**Last updated:**

23/07/2024

[View](/sv/documents/all-authorised-presentations/ilumetri-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ilumetri Active substance tildrakizumab International non-proprietary name (INN) or common name tildrakizumab Therapeutic area (MeSH) Psoriasis Anatomical therapeutic chemical (ATC) code L04AC

### Pharmacotherapeutic group

- Immunosuppressants
- Interleukin inhibitors

### Therapeutic indication

Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.

## Authorisation details

EMA product number EMEA/H/C/004514 Marketing authorisation holder

Almirall, S.A.

Ronda General Mitre, 151

Opinion adopted 25/07/2018 Marketing authorisation issued 17/09/2018 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ilumetri : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (138.07 KB - PDF)

**First published:** 16/07/2025

[View](/en/documents/procedural-steps-after/ilumetri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ilumetri : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (213.91 KB - PDF)

**First published:** 16/04/2019

**Last updated:** 16/07/2025

[View](/en/documents/procedural-steps-after/ilumetri-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Ilumetri : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/664213/2018

English (EN) (5.98 MB - PDF)

**First published:** 09/10/2018

[View](/en/documents/assessment-report/ilumetri-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ilumetri

Adopted

Reference Number: EMA/CHMP/464222/2018

English (EN) (67.52 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 27/07/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ilumetri_en.pdf)

#### News on Ilumetri

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

#### More information on Ilumetri

- [EMEA-001451-PIP01-13-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001451-pip01-13-m01)
- [Shortening the time to confirm or to rebut Adverse events of interest related to innovative Therapies for immune-mediated inflammATory dIseases: cross-talking between different data sOURces. SATURATIOn study. - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000207)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 16/07/2025

## Share this page

[Back to top](#main-content)